Open access
Sep 2026
Understanding tumor adaptations and resistance to MET inhibitors in MET-altered non-small cell lung cancer
Highlights • MET inhibitor resistance is heterogeneous across distinct MET-altered NSCLC.• Spatial transcriptomics reveal shared ECM remodeling in tumors upon progression.• In vitro models partially recapitulate aspects of clinical MET inhibitor resistance.• CRISPR and combination drug screens reveal overlapping functi...
M. Simard, E. Marin, S. García-Román et al.
· Neoplasia · 0 citations